


YKL-40 is marker of mortality in hospitalized patients

November 20 2012



For patients admitted to the hospital, the inflammatory biomarker YKL-40 is a strong predictor of mortality, regardless of diagnosis, according to a study published online Nov. 12 in the *Journal of Internal Medicine*.

(HealthDay)—For patients admitted to the hospital, the inflammatory biomarker YKL-40 is a strong predictor of mortality, regardless of diagnosis, according to a study published online Nov. 12 in the *Journal of Internal Medicine*.

In an effort to examine the <u>prognostic value</u> of YKL-40 in an unselected patient population, Naja Dam Mygind, M.D., from Rigshospitalet in Copenhagen, Denmark, and colleagues analyzed <u>blood samples</u> from 1,407 consecutive acute patients (>40 years) admitted to hospital during a one-year period. Patients were followed for a median of 11.47 years.

The researchers found that, compared with healthy controls, median



YKL-40 was significantly increased in patients (157 versus 40 µg/L). Compared with patients with YKL-40 in the lowest quartile, those with YKL-40 in the highest quartile had a significantly elevated hazard ratio (HR) for all-cause mortality in the first year (HR, 7.1) and in the total study period (HR, 3.4). Compared to patients with YKL-40 below the normal age-corrected 95-percentile, patients with YKL-40 above that level had a significantly increased risk of death (HRs, 2.1 after one-year and 1.5 during the total study period). Based on multivariate analysis, YKL-40 was an independent <u>biomarker</u> of mortality, which was most significant in the first year, and was a marker of <u>prognosis</u> in all disease categories. Independent of disease type, the HR for death was increased for those with YKL-40 above the 95th percentile, compared with healthy subjects.

"The level of YKL-40 at admission is a strong predictor of overall mortality, independent of diagnosis, and could be useful as a biomarker in the acute evaluation of all patients," the authors write.

One author is listed on a European patent relating to YKL-40. Quidel provided some of the YKL-40 assay kits.

More information: Abstract

Full Text (subscription or payment may be required)

Copyright © 2012 <u>HealthDay</u>. All rights reserved.

Citation: YKL-40 is marker of mortality in hospitalized patients (2012, November 20) retrieved 27 April 2024 from https://medicalxpress.com/news/2012-11-ykl-marker-mortality-hospitalized-patients.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.